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Namkung W, Yoon JS, Kim KH, Lee MG. PAR2 exerts local
protection against acute pancreatitis via modulation of MAP kinase
and MAP kinase phosphatase signaling. Am J Physiol Gastrointest
Liver Physiol 295: G886–G894, 2008. First published August 28,
2008; doi:10.1152/ajpgi.00053.2008.—During acute pancreatitis, pro-
tease-activated receptor 2 (PAR2) can be activated by interstitially
released trypsin. In the mild form of pancreatitis, PAR2 activation
exerts local protection against intrapancreatic damage, whereas, in the
severe form of pancreatitis, PAR2 activation mediates some systemic
complications. This study aimed to identify the molecular mecha-
nisms of PAR2-mediated protective effects against intrapancreatic
damage. A mild form of acute pancreatitis was induced by an
intraperitoneal injection of caerulein (40 g/kg) in rats. Effects of
PAR2 activation on intrapancreatic damage and on mitogen-activated
protein (MAP) kinase signaling were assessed. Caerulein treatment
activated extracellular signal-regulated kinase (ERK) and c-Jun NH2-
terminal kinase (JNK) within 15 min and maintained phosphorylation
of ERK and JNK for 2 h in the rat pancreas. Although PAR2
activation by the pretreatment with PAR2-activating peptide (AP)
itself increased ERK phosphorylation in rat pancreas, the same treat-
ment remarkably decreased caerulein-induced activation of ERK and
JNK principally by accelerating their dephosphorylation. Inhibition of
ERK and JNK phosphorylation by the pretreatment with MAP/ERK
kinase (MEK) or JNK inhibitors decreased caerulein-induced pancre-
atic damage that was similar to the effect induced by PAR2-AP.
Notably, in caerulein-treated rats, PAR2-AP cotreatment highly in-
creased the expression of a group of MAP kinase phosphatases
(MKPs) that deactivate ERK and JNK. The above results imply that
downregulation of MAP kinase signaling by MKP induction is a key
mechanism involved in the protective effects of PAR2 activation on
caerulein-induced intrapancreatic damage.
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ACUTE PANCREATITIS is a potentially lethal clinical condition with
an increasing incidence. About 20% of patients develop a
severe form of acute pancreatitis that is frequently associated
with intraabdominal or systemic complications (24). Despite
recent advances in the pathophysiological understanding of
pancreatitis, diagnostic tools, and supportive care, the overall
mortality from the severe form of the disease is still high (32).
During the disease course, various pathophysiological re-
sponses occur in intra- or peripancreatic regions including
edema, inflammation, and acinar cell damage. However, the
molecular mechanisms that underlie these processes remain
poorly understood.
Protease-activated receptor 2 (PAR2) is a member of the G
protein-coupled receptor superfamily that is activated by pro-
teolytic cleavage of its extracellular NH3-terminal domain by
trypsin, mast cell tryptase, and other serine proteases (2). The
exposed NH3-terminal peptide sequence produced by this pro-
teolysis acts as a tethered ligand that binds to and activates the
receptor. PAR2-activating peptide (PAR2-AP), a synthetic
peptide corresponding to the tethered ligand, can selectively
activate PAR2. Recent studies have suggested that PAR2 plays
a critical role in the regulation of inflammatory responses in the
gastrointestinal tract (33). Interestingly, PAR2 activation not
only triggers a proinflammatory response but also mediates
anti-inflammatory effects in the gastrointestinal tract and other
organs. For example, PAR2 activation has been reported to
have both proinflammatory and anti-inflammatory effects in
colonic inflammation (3, 10). Although several mechanisms
have been employed to explain these opposite effects of PAR2,
a more detailed understanding of the roles of PAR2 in inflam-
matory diseases is needed to develop new therapeutics based
on PAR2 modulation. In this regard, our recent study showing
the differential effects of PAR2 activation on acute pancreatitis
offered new insights into understanding the pathophysiological
role of PAR2 in inflammatory diseases (21).
An interesting feature of acute pancreatic inflammation is
the release of activated trypsin to the pancreatic interstitium
and systemic circulation (27), which can activate PAR2 during
the disease course. We have demonstrated that PAR2 may have
a dual role in acute pancreatitis, locally protecting pancreatic
acinar and duct cells against pancreatitis-induced cell damage
while mediating or aggravating the systemic complications of
acute pancreatitis (21). These dual roles of PAR2 in acute
pancreatitis were reproduced in successive studies performed
by other groups (19, 29, 30). Activation of immune and
endothelial cells would be the main pathogenic mechanisms
responsible for the proinflammatory effects of PAR2 on sys-
temic complications of acute pancreatitis (21). However, the
mechanisms related to the local protective effects of PAR2 on
acute pancreatitis remain to be elucidated.
In this study, molecular targets for the PAR2-mediated
protective effects against acute pancreatitis were investigated
in the mild form of the caerulein-induced pancreatitis model,
especially in relation to the mitogen-activated protein (MAP)
kinase signaling, because 1) PAR2 can activate MAP kinases
in pancreas and other tissues (7, 21, 31) and 2) activation of
MAP kinases is one of the key pathogenic mechanisms in
pancreatitis and other inflammatory diseases (17, 28). Contrary
to our initial expectations, PAR2 activation remarkably de-
creased the caerulein-induced activation of extracellular signal-
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regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK)
by accelerating their dephosphorylation in rat pancreas mainly
via induction of MAP kinase phosphatases (MKPs). Accord-
ingly, inhibition of ERK and JNK signaling by pharmacolog-
ical inhibitors significantly decreased intrapancreatic damage
that was similar to the effect observed with PAR2 activation.
These results suggest that downregulation of MAP kinase
signaling by MKP induction is a key mechanism involved in
the intrapancreatic protective effects of PAR2 and provide
insights for developing PAR2-based therapies in acute pancre-
atitis.
MATERIALS AND METHODS
Animals and reagents. This study was approved by the Committee
for the Care and Use of Laboratory Animals, Yonsei University
College of Medicine. Male Sprague-Dawley rats, weighing 150–200
g, were used for the animal experiments. The animals were housed
with a 12-h light/dark cycle at 23°C and fed standard laboratory chow.
Before each experiment, the rats were fasted overnight and allowed
free access to water. PAR2-AP (SLIGRL-NH2) was synthesized at the
Korea Basic Science Institute (Seoul, Korea). Fura-2 AM was pur-
chased from Molecular Probes (Eugene, OR). PD98059 and U0126
were purchased from Calbiochem (San Diego, CA). All the other
chemicals including caerulein and SP600125 were purchased from
Sigma (St. Louis, MO).
Induction of caerulein-induced pancreatitis and morphological
studies. To assess the local protective effect of PAR2 activation,
secretagogue-induced pancreatitis was elicited by a single intraperi-
toneal (ip) injection of 40 g/kg caerulein. Rats were divided into four
groups, those treated with 1) saline (control), 2) PAR2-AP (2 mg/kg
ip), 3) caerulein, and 4) PAR2-AP with caerulein. In the case of
PAR2-AP-treated groups, animals were pretreated with PAR2-AP 5
min before caerulein injection. In a set of experiments, the MAP/ERK
kinase (MEK) inhibitors, U0126 (3 mg/kg) and PD98059 (5 mg/kg),
were dissolved in DMSO and sonicated with 1% pluronic F68 and
then administered by an ip injection 1 h before caerulein treatment to
prevent ERK1/2 activation (5). The JNK inhibitor, SP600125 (10
mg/kg), was dissolved in DMSO, mixed with saline, and then admin-
istered by an ip injection 2 h before the caerulein treatment (20). At
designated times after the caerulein injection (2 h in most cases), rat
pancreata were removed and the wet weight of the pancreas was
rapidly measured after trimming of fat tissues and lymph nodes. Part
of the pancreas was then taken for immunoblot analysis and mRNA
preparation. The remaining part of the pancreas was fixed in 10%
formaldehyde and used for hematoxylin and eosin (H & E) staining.
H & E staining and morphometric analysis were performed as previ-
ously described (21).
Immunoblotting. Immunoblotting of protein samples from rat pan-
creata was performed as previously described (21). The separated
proteins were blotted with phosphorylation-specific or total protein
antibodies against ERK1/2, JNK, p38 MAP kinase, and MEK1. The
anti-phospho-MEK1 antibody was from Sigma and anti-MKP1 anti-
body from Santa Cruz (Santa Cruz, CA). All other primary antibodies
were purchased from Cell Signaling Technology (Danvers, MA).
Densitometric analysis of the immunoblot was performed with the
TINA 2.0 software (Raytest Isotopenmessgerate, Straubenhardt, Ger-
many).
Measurements of free cytosolic Ca2. Rat pancreatic acini were
isolated as previously reported (15), except for the use of collagenase
CLS4 (Worthington, Lakewood, NJ). The standard perfusate was
termed solution A and contained in (in mmol/l) 140 NaCl, 5 KCl, 1
MgCl2, 1 CaCl2, 10 D-Glucose, and 10 HEPES (pH 7.4 with NaOH).
To stabilize isolated pancreatic acinar cells, the acinar cells were
cultured in Waymouth’s MB751/1 medium at 37°C for 4 h. After
stabilization, the free cytosolic Ca2 concentration ([Ca2]i) of pan-
creatic acini was measured with the use of the Ca2-sensitive fluo-
rescent probe Fura-2 as previously described (15). Briefly, pancreatic
acini were incubated for 30 min in the Fura-2 AM (5 M) containing
solution A, which was supplemented with pyruvate (10 mM), bovine
serum albumin (0.1%), and soybean trypsin inhibitor (0.02%). Fura-
2-loaded acini were plated on coverslips that formed the bottom of a
superfusion chamber. After 2–3 min of incubation at room temper-
ature, acini were superfused for at least 10 min with warm (37°C)
solution A to remove unattached cells and soybean trypsin inhib-
itor. The attached acini were superfused with appropriate solutions
containing desired concentrations of PAR2-AP or caerulein. Fura-2
fluorescence excited at 350 and 380 nm was measured with a
photon-counting system (Delta Ram; PTI, Brunswick, NJ).
RT-PCR and real-time PCR. The mRNA transcripts of MKPs in rat
pancreatic tissues were analyzed by the semiquantitative RT-PCR and
real-time PCR. Total RNA was extracted by using a Trizol solution
(Invitrogen, Carlsbad, CA), and an equal amount of RNA (2 g) from
each sample was reverse transcribed by using an oligo (dT) primer
and RNase H- reverse transcriptase (Invitrogen). The complementary
DNA was amplified with specific primers and a Taq polymerase
(Promega, Madison, WI). To semiquantify the amount of each MKP
mRNA transcript, the logarithmic increasing phase of PCR was
determined using serially diluted cDNA samples in each set of
experiments. The band intensities of the PCR products were analyzed
by densitometry (Raytest Isotopenmessgerate). The real-time PCR on
the mRNA transcripts of PAC1, MKP1, VH3, and MKP3 was per-
formed using the ABI 7300 real-time PCR system (Applied Biosys-
tems, Foster City, CA) and the SYBR green PCR Master Mix
(Applied Biosystems) as previously described (22). The PCR primer
sets used in this study are summarized in Supplementary Table 1.
Supplemental information for this article is provided at the American
Journal of Physiology Gastrointestinal and Liver Physiology website.
Serum amylase assay. To quantitate the extent of pancreatic
inflammation, serum amylase levels were determined using the
EnzChek Ultra amylase assay kit (Invitrogen). Briefly, blood samples
were centrifuged for 20 min at 3,000 g for serum separation. Serum
was reacted with a starch substrate, which is designed to yield
fluorescent fragments when degraded by amylase. The fluorescence of
reactants was measured at an excitation wavelength of 485 nm and an
emission wavelength of 520 nm. The -amylase from Bacillus species
(Sigma) was used as a standard for calibration.
Statistical analysis. The results of multiple experiments are pre-
sented as the means  SE. Statistical analysis was performed with
1) Student t-tests (JNK phosphorylation, Fig. 3B) or with 2) analysis
of variance followed by Tukey’s multiple comparison test (all other
comparisons) using the GraphPad Prism software package (version
4.0; GraphPad Software, San Diego, CA). P  0.05 was considered
statistically significant.
RESULTS
Effect of PAR2 activation on cell signaling in caerulein
pancreatitis. A single supramaximal dose of caerulein (40
g/kg ip) was administered to rats to evoke a mild form of
acute pancreatitis. Activation of PAR2 was induced by an ip
injection of PAR2-AP (2 mg/kg) 5 min before caerulein injec-
tion. Two hours after caerulein injection, the rat pancreata were
collected and weighed to assess the extent of edema. As shown
in Fig. 1A, the injection of caerulein resulted in edema, as
evidenced by the increased pancreatic wet weight from 0.51 
0.02% to 1.02  0.08% (pancreas wt/body wt). Notably,
pretreatment with PAR2-AP reduced the extent of edema,
resulting in a pancreatic wet weight of 0.67  0.04%. This
result consisted of a 69% reduction in the caerulein-induced
edema and confirmed the protective effects of PAR2 activation
on intrapancreatic damage.
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Caerulein is a CCK receptor agonist, which can increase in
[Ca2]i in pancreatic acinar cells. An aberrant increase in [Ca2]i
is associated with cell damage and cell death in pancreatic acini
(15). Although initial activation of PAR2 evokes a strong Ca2
signaling, the Ca2 response undergoes a rapid desensitization
by consecutive PAR2 stimulations in pancreatic acinar cells
(21). Therefore, PAR2 may protect pancreatic acinar cells from
damage by preventing a caerulein-induced [Ca2]i increase. To
investigate this possibility, [Ca2]i was measured in freshly
isolated pancreatic acinar cells after consecutive PAR2 and
caerulein stimulations. As shown in Fig. 1B, repetitive treat-
ments with PAR2-AP greatly diminished [Ca2]i increase.
However, PAR2 activation did not affect the CCK receptor-
induced [Ca2]i increase by caerulein in rat pancreatic acinar
cells. These findings imply that the protective effect of PAR2
on caerulein pancreatitis is not due to the downregulation of
Ca2 signaling.
The MAP kinases play an important role in inflammation
through the regulation of inflammatory gene expression (17,
28). We previously found that PAR2 activation induces ERK
signaling in isolated pancreatic acinar cells (21). Therefore, to
assess the effects of PAR2 activation on MAP kinase signaling
in caerulein-induced pancreatitis, the phosphorylation of ERK,
JNK, and p38, which determines the activity of these MAP
kinases, was examined (Fig. 1C). Rat pancreata were collected
2 h after caerulein injection, and protein samples were immu-
noblotted with the phospho-specific or total protein antibodies
against MAP kinases. Caerulein injection induced hyperphos-
phorylation of ERK and JNK in the rat pancreas 2 h after the
injection, whereas the phosphorylation of p38 was not signif-
icantly affected. As reported previously (21), PAR2-AP treat-
ment alone induced phosphorylation of ERK1/2 although its
intensity was smaller than that of caerulein. Interestingly, when
the tissues were examined 2 h after the caerulein injection,
PAR2-AP pretreatment greatly diminished the caerulein-in-
duced phosphorylation of ERK and JNK (Fig. 1C). Densito-
metric analysis of the phospho-ERK1/2 (pERK1/2) band in-
tensity revealed that caerulein treatment induced a 13.1 
3.3-fold increase compared with control, and the pretreatment
with PAR2-AP decreased the level to 4.0  1.1-fold. There-
fore, the PAR2-AP pretreatment produced a 75% reduction in
the caerulein effect.
PAR2 accelerates dephosphorylation of ERK and JNK. CCK
receptor stimulation in rat pancreas induces the activation of
ERK1/2 and JNK within 15 min and peaks after 30 min both
in vivo and in vitro (6). Therefore, we assessed the effect of
PAR2 activation on the time course of ERK and JNK phos-
phorylation to identify the mechanisms associated with the
PAR2-mediated inhibition of the caerulein-induced effects. A
representative example of one of the immunoblots used for
measuring ERK phosphorylation is presented in Fig. 2A, and
the summarized densitometric analyses from three separate
experiments are depicted in Fig. 2B. Interestingly, PAR2-AP
pretreatment did not affect the caerulein-induced ERK phosphor-
ylation up to its peak level at 30 min, but the PAR2-AP greatly
decreased the phosphorylation status of ERK 1 h after the caer-
ulein injection. Similar results were also obtained in the experi-
ments measuring JNK phosphorylation (Fig. 3). Caerulein injec-
tion induced a hyperphosphorylation of JNK that peaked at 30
min, whereas PAR2-AP treatment alone did not induce a discern-
Fig. 1. Effect of protease-activated receptor 2 (PAR2) activation on pancreatic wet weight and cell signaling in caerulein pancreatitis. A: pancreatic wet weight
relative to body weight was measured 2 h after caerulein injection (40 g/kg ip). PAR2-activating peptide (AP) (2 mg/kg) was pretreated 5 min before caerulein
injection. Data shown are means SE from 8 separate experiments. B: free cytosolic calcium concentration ([Ca2]i) was measured in isolated pancreatic acinar
cells with the consecutive stimulation of PAR2-AP and caerulein. C: rat pancreata were collected 2 h after caerulein injection, and protein samples were
immunoblotted with phospho-specific or total protein antibodies against ERK, JNK, or p38 MAP kinases. **P  0.01 difference from caerulein.
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able increase in JNK phosphorylation. Notably, pretreatment with
PAR2-AP remarkably decreased caerulein-induced phosphoryla-
tion of JNK 1 h after the caerulein injection. These results highly
suggest that PAR2 downregulates caerulein-induced MAP kinase
signaling by accelerating dephosphorylation mechanisms rather
than by inhibiting the MAP kinase-activating processes.
Effect of ERK and JNK inhibition on caerulein-induced
pancreatitis. Although PAR2 sufficiently downregulated the
caerulein-induced ERK/JNK phosphorylation, these find-
ings do not necessarily mean that this effect of PAR2 is the
key mechanism of PAR2-mediated pancreatic protection in
acute pancreatitis. Therefore, the effects of MAP kinase
inhibition on cell damage were evaluated compared with
PAR2 activation. The MAP kinase inhibitors and PAR2-AP
were pretreated 1 h (or 2 h) and 5 min before the caerulein
injection, respectively, as detailed in MATERIALS AND METH-
ODS. As shown in Figs. 4 and 5, pretreatment with the MEK
inhibitors, U0126 and PD98059, which inhibit the downstream
ERK activation, and with the JNK inhibitor, SP600125, sig-
nificantly decreased caerulein-induced pancreatic damages.
PAR2-AP, U0126, PD98059, and SP600125 greatly amelio-
rated the pathological changes in the pancreatic tissue such as
apoptotic nuclei, interstitial edema, and the intracellular vacu-
oles that are frequently observed in the pancreatic tissues of
rats treated with caerulein alone (Fig. 4).
Morphometric analysis by counting apoptotic nuclei re-
vealed that pretreatments with PAR2-AP, U0126, PD98059,
and SP600125 significantly decreased the caerulein-induced
cell death (Fig. 5A). In addition, U0126, PD98059, and
SP600125 pretreatments all induced a 50–80% reduction in
the caerulein-induced pancreatic edema formation, which is
comparable to that of PAR2-AP (Fig. 5B). Release of pancre-
atic digestive enzymes to the blood stream is an indicative
marker of early pancreatic injury (21, 27). As shown in Fig.
5C, amylase levels in rat serum were greatly increased at 2 h
after caerulein injection, and the increase in serum amylase
was reduced 52% by PAR2-AP pretreatment. Similarly, pre-
treatments with U0126, PD98059, and SP600125 induced a
40–70% reduction in the caerulein-induced amylase increase.
Inhibition of MAP kinase signaling in rat pancreas by ERK
and JNK inhibitors was confirmed by immunoblotting with
phospho-specific antibodies. U0126 and PD98058 inhibited the
caerulein-induced ERK phosphorylation by an average of 71%
and 88% (n  5), respectively, and SP600125 inhibited the
caerulein-induced JNK phosphorylation by 93% (n  5) (Fig.
5D). Vehicles for the ERK and JNK inhibitors did not affect
the phosphorylation status of ERK and JNK. In addition, a
Fig. 2. Effect of PAR2 activation on the time course of caerulein-induced
ERK1/2 phosphorylation. Pancreatic tissues were obtained from different time
periods after the intraperitoneal injection of caerulein, and phosphorylation of
ERK1/2 was then measured by immunoblotting with anti-phospho-ERK1/2
and anti-total-ERK1/2 antibodies. A: representative immunoblot. B: summa-
rized results of densitometric analysis from 3 separate sets of experiments.
*P  0.05 difference from caerulein.
Fig. 3. Effect of PAR2 activation on the time course of caerulein-induced JNK
phosphorylation. Pancreatic tissues were obtained from different time periods
after the intraperitoneal injection of caerulein, and phosphorylation of JNK
(p54 and p46) was then measured by immunoblotting with anti-phospho-JNK
and anti-total-JNK antibodies. A: representative immunoblot. B: summarized
results of densitometric analysis from 3 separate sets of experiments. The peak
band intensity levels from rats treated with caerulein alone in each set of
experiments was used as a densitometric standard. *P  0.05 difference from
caerulein.
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partial cross inhibition was noticed between ERK and JNK
inhibitors. For example, the JNK inhibitor SP600125 inhib-
ited ERK phosphorylation by an average of 53% (n  4)
(Fig. 5D).
Effect of PAR2 activation on the expression of MKPs. Next,
mechanisms responsible for the PAR2-mediated downregula-
tion of MAP kinase signaling were investigated by exploring
the molecular machineries that regulate the phosphorylation
status of ERK and JNK. MEK1/2 are known as the key
enzymes that phosphorylate ERK1/2 (17, 28). Therefore, to
explore the PAR2 effects on the upstream signals of ERK, the
activity of MEK was investigated using phospho-specific
MEK1 antibodies (Fig. 6A). Caerulein treatment induced an
activation/phosphorylation of MEK1 in rat pancreas. However,
PAR2-AP pretreatment did not affect the caerulein-induced
MEK1 phosphorylation. This result suggests that PAR2 may
not affect the activation process of ERK1/2 phosphorylation.
MKPs are a family of enzymes that can dephosphorylate
MAP kinases, which in turn switch off MAP kinase signaling.
MKPs are divided into three major categories depending on
their preference for tyrosine dephosphorylation (tyrosine-spe-
cific MKPs; TS-MKPs), serine/threonine dephosphorylation
(serine/threonine-specific MKPs; SS-MKPs), or both (dual
specificity MKPs; DS-MKPs) (9, 14). MKPs are predomi-
nantly regulated through transcriptional induction by the acti-
vated downstream signals of MAP kinases (9, 14). Therefore,
MKP mRNA expression levels were analyzed first using the
semiquantitative RT-PCR assay as described in the legend of
Fig. 6. Notably, PAR2-AP cotreatment highly increased the
mRNA transcripts of a group of MKPs including MKP1,
MKP3, PAC1, and VH3 in caerulein-treated rats (Fig. 6B).
Densitometric analysis revealed that the PAR2-AP pretreat-
ment always evoked more than fivefold increases in PAC1,
MKP1, VH3, and MKP3 mRNAs compared with those in the
rats treated with caerulein alone (n  3). mRNA transcripts of
these MKPs were then further quantified using the real-time
PCR assay (Fig. 7A). The PAR2-AP cotreatment in the caerulein-
treated rats induced 23.5 (MKP3) to 26.8 (PAC1)-fold in-
creases in the pancreatic mRNA levels compared with those in
the control rats and were 23.4 (MKP3) to 25.6 (PAC1)-fold
higher than those in the rats treated with caerulein alone (Fig.
7A). Finally, MKP1 protein expression was analyzed by im-
Fig. 4. Effect of ERK and JNK inhibition on pancreatic tissue damage. Light microscopic images of hematoxylin and eosin staining were obtained from paraffin
sections of pancreata collected 2 h after the caerulein injection (40 g/kg ip). The MAP/ERK (MEK)1/2 inhibitors, U0126 (3 mg/kg ip) and PD98059 (5 mg/kg
ip), were administered with 1 h before caerulein injection, and the JNK inhibitor, SP600125 (10 mg/kg ip), was treated with 2 h before caerulein injection.
A and B: pancreatic sections of the control and PAR2-AP-treated group showed well-preserved acinar and islet structures. C, E, and H: pancreas sections from
rats treated with caerulein, either alone or with vehicles for MAP kinase inhibitors, showed apoptotic nuclei (arrow 1), interstitial edema (arrow 2), and
intracellular vacuoles (arrow 3). D, F, G, and I: pretreatments with PAR2-AP or the inhibitors of ERK and JNK attenuated pancreatic damage in
caerulein-induced pancreatitis. A scale bar at each right lower corner represents 20 m.
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munoblotting (Fig. 7B). MKP1 protein was undetectable in
pancreata from control rats. Stimulations with PAR2-AP
occasionally evoked a detectable increase in MKP1 protein,
whereas caerulein constantly induced MKP1 expressions to
a certain level. Notably, the PAR2-AP cotreatment greatly
increased the caerulein-induced MKP1 protein expression
by an average of 4.8-fold when compared with caerulein
alone (Fig. 7B).
Fig. 5. Effect of MAP kinase inhibition on the quantitative
parameters of acute pancreatitis and MAP kinase signaling.
A: morphometric analysis of apoptotic nuclei count was per-
formed using the light microscopic images of hematoxylin and
eosin staining of pancreas collected 2 h after caerulein injection
(40 g/kg ip). The MEK and JNK inhibitors were administered
as described in the Fig. 4 legend. B: pancreatic wet weight
relative to body weight was measured 2 h after caerulein
injection. C: serum amylase levels were measured in rats 2 h
after caerulein injection. D: rat pancreata were collected 2 h
after caerulein injection, and protein samples were immunoblot-
ted with phospho-specific and total protein antibodies against
ERK and JNK. **P  0.01, *P  0.05 difference from
caerulein.
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DISCUSSION
Pathogenesis of acute pancreatitis is associated with the
inappropriate premature activation of intracellular digestive
enzymes, particularly trypsin, and with the release of activated
enzymes into the pancreatic interstitium and systemic circula-
tion (12, 16, 27). In this regard, acute pancreatitis is a unique
status in which a large amount of active trypsin can stimulate
PAR2 in pancreatic tissues and the systemic circulatory sys-
tem. PAR2 activation in pancreatic acinar and duct cells serves
to protect intrapancreatic cell damages, whereas PAR2 activa-
tion in systemic inflammatory cells is associated with early
fatal complications (19, 21, 29, 30). In this study, molecular
targets for the PAR2-mediated protective effects against in-
trapancreatic damage were investigated in the mild form of
acute pancreatitis. Our results revealed that the key mechanism
of PAR2-mediated protective effects is the downregulation of
MAP kinase signaling through the induction of MKPs.
Downregulation of the caerulein-induced ERK and JNK
phosphorylation by PAR2 was rather unexpected considering
the fact that PAR2 activation itself induces the phosphorylation
of ERK in isolated pancreatic acini (21) and many other cell
types (7, 31). A series of experiments in the present study
indicated that the PAR2-mediated MAP kinase downregulation
was attributable to an accelerated dephosphorylation after the
phosphorylation reached a peak level by the caerulein treat-
ment. Activation of MAP kinases and the consecutive activa-
tion of downstream transcription factors result in the immedi-
ate transcription of MKP genes as well as the transcription of
genes encoding cytokines and other cellular proteins (9, 14).
The expression of MKPs provides a major negative feedback
regulatory mechanism for MAP kinase activity, but the de-
tailed mechanism remains largely unknown. To date, nearly 30
proteins are known to have MKP activity, including 13 DS-
MKPs (9). Our results revealed that either PAR2 or caerulein
stimulation can induce MKP expressions. However, most im-
portantly, costimulation of both PAR2 and caerulein synergis-
tically increased the expressions of a group of MKPs including
PAC1, MKP1, VH3, and MKP3. This would not only cause an
accelerated dephosphorylation of MAP kinases, but also simul-
taneously induce a cross downregulation of several MAP
kinase signaling cascades.
Recently, Sharma et al. (29) reported that PAR2 activation
inhibited the caerulein-induced nuclear translocation of pERK1/2
without affecting the cytosolic pERK1/2 levels when measured
30 min after the injection of caerulein. This result may be in
Fig. 6. Effect of PAR2 activation on MEK1
phosphorylation and on MKP expression. A: rat
pancreata were collected 2 h after caerulein in-
jection, and protein samples were immunoblot-
ted with phospho-specific or total protein anti-
bodies against MEK1. B: MKP mRNA expres-
sion levels were analyzed using the semi-
quantitative RT-PCR. The logarithmic increasing
phase of PCR was determined using serially
diluted cDNA samples. An initial PCR (30 cy-
cles) using cDNAs transcribed from 0.1 g
RNA sample of control rats usually produced a
high-intensity band. PCR reactions were re-
peated with serially 10-fold diluted cDNA sam-
ples until the disappearance of PCR band in the
ethidium bromide (0.2 g/ml) staining. The di-
lution factor that produced a PCR band around
10–30% of the initial maximum intensity was
chosen for comparison of mRNA samples in
each set of experiments. Three separate sets of
experiments showed similar results. DS-MKP,
dual-specificity MKP; TS-MKP, tyrosine-specific
MKP; SS-MKP, serine/threonine-specific MKP.
Fig. 7. Quantitative measurements of MKP expressions. A: real-time PCR
measuring mRNA transcripts of PAC1, MKP1, VH3, and MKP3. Data shown
are means SE from 4 separate sets of experiments. The amount of each MKP
mRNA was normalized to that of 18S rRNA by using the 2		CT (CT,
threshold cycle) method, where 		CT  (CTMKPs  CT18SrRNA)Treatment 
(CTMKPs  CT18SrRNA)Control. B: immunoblotting of MKP1 from 4 separate
sets of experiments.
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partial agreement with our study. However, our results are
different in several aspects. For example, the major effect of
PAR2 activation on MAP kinase signaling in our study is the
augmentation of the dephosphorylation process through the
induction of MKPs rather than the inhibition of ERK activation
at earlier time points. Moreover, PAR2 activation downregu-
lates the caerulein-induced JNK phosphorylation as well as
ERK phosphorylation.
Although precise downstream effector systems are not fully
understood yet, it is generally accepted that early activation of
ERK and JNK plays an important role in the initiation and
progression of pancreatic damage during acute pancreatitis (8,
11, 34). Of note, JNK activation has been suggested to play a
major role in caerulein-induced pancreatitis as a stress kinase
and mediator of apoptotic pathway (28). Accordingly, inhibi-
tion of ERK and JNK signaling by pharmacological inhibitors
has been shown to decrease pancreatic damage in experimental
pancreatitis (5, 20), which was similar to the effect observed
with PAR2 activation in our study (Figs. 4 and 5). An unex-
pected finding in our study is the cross-inhibitory effect be-
tween inhibitors of MEK/ERK signaling and JNK signaling in
caerulein pancreatitis. Of the two MEK inhibitors used in the
present study, U0126 is a very specific inhibitor for MEK1/2
and does not inhibit enzymes in the JNK signaling cascades.
Also, PD98059 does not inhibit JNK when used at a concen-
tration below 100 M. The JNK inhibitor SP600125 has
greater than a 300-fold selectivity for JNK over ERK1/2 (1).
However, it was found that SP600125 decreased not only the
phosphorylation of JNK but also the phosphorylation of ERK
(Fig. 5D), whereas the U0126 and PD98059 MEK inhibitors
exhibited the opposite result in rat pancreas (Supplementary
Fig. 1). These results imply that a crosstalk exists between
ERK and JNK signaling in caerulein-induced rat pancreatitis,
as it has been suggested previously in several other systems (4,
26, 28). Alternatively, the MEK/ERK and JNK inhibitors may
have a cross-inhibitory effect in a cell-specific manner or
in vivo state as once reported in mouse pancreatitis (20).
An intriguing feature of PAR2 activation is its dual effects
on the pathogenesis of acute pancreatitis. It has been shown
that PAR2 activation has protective effects on the mild form of
acute pancreatitis (e.g., caerulein-induced pancreatitis) while
aggravating the severe form of acute pancreatitis (e.g., tauro-
cholate-induced pancreatitis) (19, 21, 29, 30). Considering the
present results, these dual effects can be due to the differential
activation of MAP kinases and MKPs. For example, in the case
of the mild form of pancreatitis, PAR2 activation evokes a
weak ERK activation, which facilitates the downstream acti-
vation of MKPs. However, in the severe form of pancreatitis,
pathological stress-induced MAP kinase activation is too
strong to be nullified by MKPs, and thus PAR2-induced MAP
kinase activation would aggravate the inflammatory process by
the progressive activation of proinflammatory signals, espe-
cially in the systemic inflammatory cells. During submission of
the present manuscript for publication, Laukkarinen et al. (18)
reported an interesting result that would be compatible with our
results. PAR2 deletion exerted contrasting model-specific ef-
fects on acute pancreatitis, a protective effect on taurocholate-
induced pancreatitis, and a worsening effect on caerulein-
induced pancreatitis, and those effects were correlated with
JNK activation. Taken together, results from our study and
Laukkarinen et al. suggest that differential activations of MAP
kinase and MKPs play an important role in the dual effects of
PAR2 activation on acute pancreatitis.
Previously, we have observed that PAR2 can activate both
short-term signals (e.g., [Ca2]i increase) and long-term sig-
nals (e.g., ERK activation) in rat pancreatic acinar cells (21).
Our present findings in this study highly indicate that one of the
long-term signals, the induction of MKPs by ERK activation,
plays a major role in the PAR2-mediated protective effects
during acute pancreatitis. However, our results do not com-
pletely exclude the possibility that PAR2 evokes a beneficial
role through the short-term signaling events. For example, we
and others have found that PAR2-mediated Ca2 signals en-
hanced exocrine secretion from pancreatic acinar and duct
cells, which may have beneficial effects on pancreatitis by
clearing away harmful substances (13, 23, 25). In fact, a recent
study suggests that PAR2 may exert beneficial effects by
stimulating the secretion of potentially harmful, activated di-
gestive enzymes from injured acinar cells in the early stage of
pancreatitis (30).
Many signals or effector systems have been reported to be
associated with the initiation or progression of acute pancre-
atitis (28). In this regard, it will be of great interest to inves-
tigate downstream signals that can be affected by the PAR2-
mediated downregulation of MAP kinase signaling. An inte-
grated knowledge of downstream effectors and the associated
signals that are modulated by the PAR2-mediated induction of
MKPs will provide better insight into our understanding of
PAR2 effects on acute pancreatitis.
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